From chip giant NVIDIA agreeing a $2 billion partnership with AI cloud provider Nebius, to Roche ramping up its investment in ...

Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed ...

Eli Lilly's injectable GLP-1 agonist medicines for obesity and diabetes drove 56% growth in first-quarter sales, but ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate ...

New guidance from reimbursement authority NICE has recommended Rystiggo (rozanolixizumab) for people with gMG who test ...

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, after Norgine's ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in ...

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to support the ...

Sanofi's Sarclisa has played second fiddle to Johnson & Johnson's Darzalex in the treatment of multiple myeloma (MM), but the company hopes a new delivery option could give it more of a leading role.

In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...